Exp Mol Med.  2013 Jan;45(1):e2.

The potential use of mesenchymal stem cells in hematopoietic stem cell transplantation

Affiliations
  • 1Department of Laboratory of Immune Regulation, Convergent Research Consortium for Immunologic Disease (CRCID), Seoul, Korea. chosg@catholic.ac.kr
  • 2The Catholic University of Korea, College of Medicine, Seoul, Korea.
  • 3Department of Hematology, Catholic Blood and Marrow Transplantation Center, Seoul St Mary's Hospital, The Catholic University of Korea, College of Medicine, Seoul, Korea.

Abstract

In the last 10 years, mesenchymal stem cells (MSCs) have emerged as a therapeutic approach to regenerative medicine, cancer, autoimmune diseases, and many more due to their potential to differentiate into various tissues, to repair damaged tissues and organs, and also for their immunomodulatory properties. Findings in vitro and in vivo have demonstrated immune regulatory function of MSCs and have facilitated their application in clinical trials, such as those of autoimmune diseases and chronic inflammatory diseases. There has been an increasing interest in the role of MSCs in allogeneic hematopoietic stem cell transplantation (HSCT), including hematopoietic stem cell engraftment and the prevention and treatment of graft-versus-host disease (GVHD), and their therapeutic potential has been reported in numerous clinical trials. Although the safety of clinical application of MSCs is established, further modifications to improve their efficacy are required. In this review, we summarize advances in the potential use of MSCs in HSCT. In addition, we discuss their use in clinical trials of the treatment of GVHD following HSCT, the immunomodulatory capacity of MSCs, and their regenerative and therapeutic potential in the field of HSCT.

Keyword

clinical trials; graft-versus-host disease; hematopoietic stem cell transplantation; mesenchymal stem cells; therapeutic use; transplantation immunology

MeSH Terms

Animals
Chimerism
Clinical Trials as Topic
Graft vs Host Disease/immunology/therapy
*Hematopoietic Stem Cell Transplantation
Humans
Immunomodulation
Mesenchymal Stromal Cells/*cytology/immunology
Full Text Links
  • EMM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr